AI MARKET SCANNING

Cullinan Therapeutics, Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP -0.41%
MAX GAP RECORD -9.04%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $CGEM
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 06, 2026 Earnings Release 2026-08-06 (BEFORE OPEN)
+0.34%
May 07, 2026 Earnings Release 2026-05-07 (BEFORE OPEN)
+0.90%
Mar 10, 2026 Earnings Release 2026-03-10 (BEFORE OPEN)
+2.81%
Nov 06, 2025 Earnings Release 2025-11-06 (BEFORE OPEN)
+0.96%
Aug 07, 2025 Earnings Release 2025-08-07 (BEFORE OPEN)
-3.43%
May 07, 2025 Earnings Release 2025-05-07 (BEFORE OPEN)
+0.51%
Feb 27, 2025 Earnings Release 2025-02-27 (BEFORE OPEN)
+2.25%
Nov 07, 2024 Earnings Release 2024-11-07 (BEFORE OPEN)
+0.12%

VOLATILITY & GAP BIAS

AVG GAP MOVE 1.9%
Bullish Gaps (3)
Bearish Gaps (5)
Neutral / Flat (7)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $CGEM

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗